A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-348 as Monotherapy, in Combination With Carboplatin or in Combination With Docetaxel in Subjects With Advanced Solid Tumors.

Trial Profile

A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-348 as Monotherapy, in Combination With Carboplatin or in Combination With Docetaxel in Subjects With Advanced Solid Tumors.

Completed
Phase of Trial: Phase I

Latest Information Update: 06 Jun 2017

At a glance

  • Drugs Ilorasertib (Primary) ; Ilorasertib (Primary) ; Carboplatin; Docetaxel
  • Indications Solid tumours
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Abbott Laboratories; AbbVie
  • Most Recent Events

    • 06 Jun 2017 Results of a pharmaco-kinetics/dynamics evaluation from NCT02540876 and NCT01110486 trials presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 01 Sep 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 26 Aug 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top